nach oben

Erschienen in:

01.03.2016 | Original Research

Ten-year outcomes for prostate cancer patients with Gleason 8 through 10 treated with external beam radiation and high-dose-rate brachytherapy boost in the PSA era

verfasst von: Alvaro A. Martinez, Chirag Shah, Nasiruddin Mohammed, D. Jeffrey Demanes, Razvan Galalae, Rafael Martinez-Monge, Mihai Ghilezan, Hong Ye

Erschienen in: Journal of Radiation Oncology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

High-dose-rate (HDR) brachytherapy boost represents a method to dose escalate in high-risk prostate cancer; the purpose of this analysis is to report long-term outcomes for a group of high-risk patients with Gleason 8 through 10 prostate cancer treated with HDR brachytherapy boost from a multi-national cohort study.

Methods

Between 1987 and 2002, 483 patients with Gleason 8–10 prostate cancer were treated on four prospective trials of HDR boost. Conformal external beam radiotherapy (EBRT) was delivered to the pelvis (dose range 36–50.4 Gy) along with HDR boost for a combined biologic equivalent dose (BED) of 215–366 Gy (α/β = 1.2) and cumulative dose of 64–72 Gy.

Results

Mean/median follow-up was 6.1/5.1 years. The 10-year rates of biochemical control (BC), distant metastases (DM), clinical failure (CF), cause-specific survival (CSS), and overall survival (OS) were 53.5, 22.1, 25.6, 82.6, and 62.7 %, respectively. Androgen deprivation was given in 69.9 % of patients (predominantly short course) but did not significantly improve BC, DM, CSS, or OS. When stratified by initial PSA (iPSA), 10-year outcomes were improved with lower iPSA (<40) including BC (57.4 vs. 10.3 %, p < 0.001); freedom from distant metastases (81.5 vs. 43.4 %, p < 0.001); CSS (85.0 vs. 59.1 %, p < 0.001); and OS (63.8 vs. 47.9 %, p = 0.02).

Conclusion

A combination of HDR brachytherapy boost and EBRT provides a high BED with high rates of disease control and excellent disease specific survival for patients with Gleason 8 through 10 prostate cancer even with iPSA up to 40 ng/ml. Hormonal therapy did not improve outcomes in this cohort of patients when the radiation dose was escalated with an HDR prostate boost.

Zelefsky MJ, Yamada Y, Fuks Z et al (2008) Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71:1028–1033CrossRefPubMed

Kuban DA, Tucker SL, Dong L et al (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67–74CrossRefPubMed

Martinez A, Gonzalez J, Spencer W et al (2003) Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol 169:974–979CrossRefPubMed

Demanes DJ, Rodriguez RR, Schour L et al (2005) High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy’s 10-year results. Int J Radiat Oncol Biol Phys 61:1306–1316CrossRefPubMed

Galalae RM, Kovacs G, Schultze J et al (2002) Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52:81–90CrossRefPubMed

Martinez-Monge R, Moreno M, Ciervide R et al (2012) External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome. Int J Radiat Oncol Biol Phys 82:e469–e476CrossRefPubMed

Hoskin PJ, Rojas AM, Brownes PJ et al (2012) Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 103:217–222CrossRefPubMed

Martin T, Roddiger S, Kurek R et al (2004) 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer. Radiother Oncol 71:35–41CrossRefPubMed

Edmundson GK, Yan D, Martinez AA (1995) Intraoperative optimization of needle placement and dwell times for conformal prostate brachytherapy. Int J Radiat Oncol Biol Phys 33:1257–1263CrossRefPubMed

10.

Edmundson GK, Rizzo NR, Teahan M et al (1993) Concurrent treatment planning for outpatient high dose rate prostate template implants. Int J Radiat Oncol Biol Phys 27:1215–1223CrossRefPubMed

11.

Grills IS, Martinez AA, Hollander M et al (2004) High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 171:1098–1104CrossRefPubMed

12.

Stewart SB, Boorjian SA (2014) Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective. Urol Oncol

13.

Abdollah F, Klett DE, Sood A et al (2014) Predicting pathologic outcomes in patients undergoing robotic-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram. BJU Int

14.

Do TM, Parker RG, Smith RB et al (2001) High-grade carcinoma of the prostate: a comparison of current local therapies. Urology 57:1121–1126CrossRefPubMed

15.

Manoharan M, Bird VG, Kim SS et al (2003) Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of >/=8. BJU Int 92:539–544CrossRefPubMed

16.

Boorjian SA, Karnes RJ, Rangel LJ et al (2008) Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8–10 cancers. BJU Int 101:299–304CrossRefPubMed

17.

Audenet F, Comperat E, Seringe E et al (2011) Oncologic control obtained after radical prostatectomy in men with a pathological Gleason score >/= 8: a single-center experience. Urol Oncol 29:602–607CrossRefPubMed

18.

Pahlajani N, Ruth KJ, Buyyonouski MK et al (2012) Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8–10 prostate cancer. Int J Radiat Oncol Biol Phys 82:1949–1956CrossRefPubMed

19.

Fang LC, Merrick GS, Butler WM et al (2011) High-risk prostate cancer with Gleason score 8–10 and PSA level ≤ 15 ng/mL treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 81:992–996CrossRefPubMed

20.

Brenner DJ, Martinez AA, Edmundson GK et al (2002) Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52:6–13CrossRefPubMed

21.

Dearnaley DP, Sydes MR, Graham JD et al (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8:475–487CrossRefPubMed

22.

Stock RG, Cesaretti JA, Hall SJ et al (2009) Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int 104:1631–1636CrossRefPubMed

23.

Boladeras A, Santorsa L, Gutieerez C et al (2014) External beam radiotherapy plus single-fraction high dose rate brachytherapy in the treatment of locally advanced prostate cancer. Radiother Oncol 112:227–232CrossRefPubMed

Titel: Ten-year outcomes for prostate cancer patients with Gleason 8 through 10 treated with external beam radiation and high-dose-rate brachytherapy boost in the PSA era
verfasst von: Alvaro A. Martinez
Chirag Shah
Nasiruddin Mohammed
D. Jeffrey Demanes
Razvan Galalae
Rafael Martinez-Monge
Mihai Ghilezan
Hong Ye
Publikationsdatum: 01.03.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Radiation Oncology / Ausgabe 1/2016
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-015-0218-3

Neu im Fachgebiet Onkologie

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Ten-year outcomes for prostate cancer patients with Gleason 8 through 10 treated with external beam radiation and high-dose-rate brachytherapy boost in the PSA era